Loading patent…
AssigneeCornell Research Foundation, Inc.
InventorsLorraine J. Gudas, Charles Achkar, Jochen Buck, Alexander W. Langston, Fadila Derguini, Koji Nakanishi
Estimating the term…
For the first time, certain retinoids with a side chain terminal CH.sub.2 OH group or ester or ether thereof or aldehyde rather than a side chain terminal COOH group and substitution at the 4-position have been indicated to bind to nuclear receptors and to be biologically active in inducing cell differentiation of normal and tumor cells. These compounds activate gene expression through binding to nuclear receptor proteins. These compounds induce differentiation in normal and cancer cells and are useful for treating leukemias, and lymphomas, squamous cell carcinomas, deep (cystic) acne, psoriasis and photodamaged or aging skin. These compounds have stability and in vitro half-life advantages over and solubility differences from all-trans-retinoic acid and activity advantages over 13-cis retinoic acid.
A method for treating deep acne in a patient afflicted with this condition comprising administering to said patient an acne clearing amount of a retinoid having the structure ##STR8## wherein the configuration at the 7-, 9-, 11- and 13-position double bonds is independently Z or E and wherein R.sub.1 is selected from the group consisting of ##STR9## wherein the keto group at the 4-position is free or protected;
A method for treating deep acne in a patient afflicted with this condition comprising administering to said patient an acne clearing amount of a retinoid having the structure ##STR11## wherein the configuration at the 7-, 9-, 11- and 13-position double bonds is independently Z or E and wherein R.sub.1 is selected from the group consisting of ##STR12## wherein the keto group at the 4-position is free or protected;
Dependencies are inferred from the claim text.